Muscular Dystrophy, Facioscapulohumeral
0
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Utah MedicalIreland - Dublin
1 programMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Utah MedicalMotor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
Human BioSciencesCHDR Monitoring Remotely
Clinical Trials (2)
Total enrollment: 138 patients across 2 trials
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
Start: May 2025Est. completion: May 202880 patients
N/ARecruiting
Digital Biotyping of FSHD Patients and Controls
Start: Apr 2019Est. completion: Oct 201958 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 138 patients
3 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.